home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A3000.TXT
< prev
Wrap
Text File
|
1994-10-25
|
4KB
|
54 lines
Document 3000
DOCN M94A3000
TI 407 patients (pts) with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL):
the experience of the GICAT (Italian Cooperative Group on AIDS and
Tumors).
DT 9412
AU Tirelli U; Spina M; Vaccher E; Nasti G; Bernardi D; Serraino D;
Rizzardini G; Fasan M; Division of Medical Oncology and AIDS, Centro di
Riferimento; Oncologico, Aviano, Italy.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):176 (abstract no. PB0132). Unique
Identifier : AIDSLINE ICA10/94369575
AB OBJECTIVE: To analyze the outcome of 407 pts with AIDS-NHL. METHODS:
Since november 1986, we have collected data on 407 pts with peripheral
AIDS-NHL observed by the GICAT. At the Aviano Cancer Center, in the same
period of time 93 pts have been treated according to prospective
protocols. Based on HIV-related prognostic factors pts with unfavourable
histology and stage III and IV were treated with intensive third
generation CT regimens (group 1, usually with CD4 > 200, good PS and
without OI), with palliative CT with just 1 or 2 drugs or local RT
(group 3, usually with CD4 < 100, poor PS and with OI) or with standard
CHOP-like CT regimens (group 2, the remaining pts). RESULTS: At
diagnosis of AIDS-NHL, CD4 < 100/mm3 were detected in 46% of the pts.
Immunoblastic and Burkitt were diagnosed in 58% and 20% of the pts,
respectively; advanced (III and IV) stage and B symptoms were present in
80% and 69% of the pts, respectively. Median survival was 6 months; by
the Cox model 4 factors were associated with a significantly shorter
survival: advanced stage, heterosexuality, no treatment received and not
having obtained a CR. The table reports the parameters that reached
statistical significance in the comparison between the 3 groups of 92
evaluable pts treated at the Aviano Cancer Center. TABULAR DATA, SEE
ABSTRACT VOLUME. A significantly higher CR rate has been observed in
group 1 pts, but with a concomitant increase of OIs during CT and follow
up, in comparison to group 2 pts. However group 1 pts had a 1.5
decreased risk of dying in comparison to group 2 and 3 pts. Overall, 13
pts with a CR lasting for at least 2 years had a 42-month median
survival with none of such pts relapsing even after 6 years. DISCUSSION
AND CONCLUSIONS: We have observed a large number of peripheral AIDS-NHL,
mainly with immunoblastic and Burkitt subtypes, advanced stage and B
symptoms. In the prospective treatment at a single institution,
intensive CT regimens were associated both to higher CR rate and higher
OIs during CT and follow up, with some pts experiencing long survival
and possibly cure.
DE Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY/
PATHOLOGY/RADIOTHERAPY Antineoplastic Agents, Combined/*THERAPEUTIC USE
Combined Modality Therapy Comparative Study Follow-Up Studies Human
Italy Leukocyte Count Lymphoma, AIDS-Related/*DRUG
THERAPY/MORTALITY/PATHOLOGY/ RADIOTHERAPY Neoplasm Staging Palliative
Treatment Prospective Studies Support, Non-U.S. Gov't Survival Rate
T4 Lymphocytes/IMMUNOLOGY MEETING ABSTRACT
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).